**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 38881**

**Manuscript Type: CASE REPORT**

**Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature**

Cho WH *et al.* Tenofovir disoproxil fumarate resistance in CHB

Woo Hee Cho, Hyun Jae Lee, Ki Bae Bang, Seok Bae Kim, Il Han Song

**Woo Hee Cho, Hyun Jae Lee, Ki Bae Bang, Seok Bae Kim, Il Han Song,** Department of Internal Medicine, Dankook University College of Medicine, Cheonan 31116, South Korea

**ORCID number:** Woo Hee Cho (0000-0003-2246-6517); Hyun Jae Lee (0000-0002-3983-4518); Ki Bae Bang (0000-0002-9961-9318); Seok Bae Kim (0000-0002-6857-9624); Il Han Song (0000-0003-3975-6342).

**Author contributions:** Cho WH, Lee HJ and Bang KB collected the patient’s clinical data; Cho WH, Kim SB and Song IH designed the report and wrote the paper.

**Informed consent statement:** The patient was not required to give informed consent for this study because this study used clinical data that were obtained after this patient agreed to treatment but before treatment initiation.

**Conflict-of-interest statement:** All authors declare no conflicts of interest related to this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** **Seok Bae Kim, MD, Professor,** Department of Internal Medicine, Dankook University College of Medicine, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, South Korea. 11961019@dankook.ac.kr

**Telephone:** +82-41-5503910

**Fax:** +82-41-5563256

**Received:** March 21, 2018

**Peer-review started:** March 21, 2018

**First decision:** March 30, 2018

**Revised:** April 1, 2018

**Accepted:** April 16, 2018

**Article in press:**

**Published online:**

**Abstract**

Tenofovir disoproxil fumarate (TDF) is a potent nucleotide analogue that is recommended as first-line therapy for patients with chronic hepatitis B. The results of a longitudinal study of TDF treatment demonstrated no development of resistance. We observed one treatment-naïve chronic hepatitis B (CHB) patient who developed TDF resistance after complete viral suppression during long-term TDF treatment. A 37-year-old HBeAg-positive man received TDF 300 mg/d for 43 mo. The hepatitis B virus (HBV) DNA titer was 8 log10 copies/mL at baseline and became undetectable at 16 mo after treatment. However, the HBV DNA titer rebounded to 7.5 log10 copies/mL at 43 mo after treatment. We performed full sequencing to find mutation sites associated with virologic breakthrough. The results showed 9 mutation sites, most of which had not been well-known as mutation sites. We changed the therapy from tenofovir to entecavir with a regimen of 0.5 mg once daily. After 4 mo, the HBV DNA titer decreased to 267 copies/mL, and the liver enzyme levels were normalized.

**Key words:** Chronic hepatitis B; Tenofovir; Resistance; Mutation

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The results of many clinical longitudinal studies of Tenofovir disoproxil fumarate (TDF) treatment have demonstrated no development of resistance until now. Recently, a few cases of resistance to TDF have been reported. However, the mutation site had not been clearly revealed and confirmed because of the rarity of resistant cases. In the present case, TDF resistance developed following the complete suppression of HBV DNA in a treatment-naïve patient. We detected 9 mutation sites, including some that have been unknown until now. We believe that the present study is helpful in revealing the exact mutation sites associated with TDF resistance.

Cho WH, Lee HJ, Bang KB, Kim SB, Song IH. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature. *World J Gastroenterol* 2018; In press

**INTRODUCTION**

Chronic hepatitis B (CHB) affects approximately 250 million people worldwide and can lead to liver cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death[1-3]. Globally, approximately 30% of cirrhosis cases and 53% of HCC cases have been attributed to CHB[2]. Antiviral therapy for hepatitis B virus (HBV) infection can suppress viral replication and halt disease progression[4,5]. The reduction of HBV DNA concentrations to very low or undetectable levels through antiviral therapy is associ­ated with a reduced risk of mortality and HCC[6-8]. However, the therapeutic benefits are diminished because of the emergence of drug-resistant viruses.

Entecavir (ETC) and tenofovir disoproxil fumarate (TDF) are the two first-line therapies recommended for the treatment of CHB because they have a more potent antiviral effect and higher genetic barriers against resistance than other antiviral agents. The rate of antiviral resistance in previously untreated patients has been reported for ETC, *i.e.*, 1.2% of patients develop resistance in 5 years[9,10]. The development of resistance to TDF has not been reported in treatment-naïve patients until now[[1](#_ENREF_12)1].

The rtA194T polymerase mutation combined with the rtL180M and rtM204V polymerase mutations is reported to be associated with TDF resistance in HIV/HBV co-infected patients[[1](#_ENREF_13)2]. However, TDF resistance-related mutations in patients infected only with HBV were unknown until now. Recently, Lee *et al*[13] reported two TDF resistance mutations in CHB patients during "The Liver Week 2017" symposium in the United States. The patients harbored CHB mutants with three new substitutions, namely, rtS106C, rtH126Y and rtD134E. These patients had previously been treated with various therapies, including lamivudine (LAM), adefovir (ADV) and ETC. We observed the development of TDF resistance in a patient who had no treatment history. This patient showed virologic and biochemical breakthroughs after he achieved a complete virologic response. In this study, we report the first case of TDF resistance in a treatment-naïve patient and review the pertinent literature.

**CASE REPORT**

The patient was a 37-year-old Korean male who visited the clinic because of elevated liver enzymes. He was first diagnosed as having chronic hepatitis B at the age of 20 and was followed up regularly in the family medicine department of Dankook University Hospital. Until his visit to the clinic, he had no history of liver enzyme elevation. His mother was also diagnosed with chronic hepatitis B but did not receive antiviral treatment. The patient’s laboratory examination showed that he was positive for HBsAg and HBeAg. His aspartate transaminase (AST) and alanine aminotransferase (ALT) levels were high, at 51 IU/L and 80 IU/L, respectively. His HBV DNA titer was greater than 8.99 log10 copies/mL, as measured by the AmplicorTM Monitor PCR assay (lower limit of detection, 116 copies/mL; Roche Diagnostics, Basel, Switzerland). Abdominal sonography revealed a diffuse mild fatty liver. No evidence of cirrhosis, such as splenomegaly, thrombocytopenia, or esophageal varices, was observed. The patient was started on Tenofovir disoproxil fumarate (TDF) 300 mg, one tablet daily. After 16 mo, the HBV DNA level was undetectable. The AST and ALT levels had also normalized to 27 IU/L and 35 IU/L, respectively. The patient continued the same treatment with complete adherence, but HBeAg was not converted. However, after 43 mo of continuous treatment, HBV DNA had increased to 7.5 log10 copies/mL. The levels of AST and ALT were also increased to 61 IU/L and 109 IU/L, respectively. The patient’s history showed that he took TDF regularly every day, and there was no history of the use of any other medicine that could either decrease the efficacy of TDF or increase its rate of metabolism. Tests for HIV and anti-HCV antibodies were negative. We performed mutation testing on the rtL80, rtI169, rtL180, rtA181, rtT184, rtA194, rtS202, rtM204, rtL220, rtN236, and rtM250 sites, all of which were previously known to be mutation sites, but all of these sites were identified as wild type. We performed further examinations on the rtS106, rtH126, rtD134, and rtL269 sites, which have been revealed as mutation sites associated with tenofovir resistance, and only the rtS106C mutation was detected. We performed full genome sequencing to find other mutation sites associated with virologic breakthrough because the rtS106C mutation alone was not sufficient to cause tenofovir resistance (Figure 1). The results showed mutations at 9 sites, namely, rtY9H, rtL91I, rtS106C, rtS106G, rtT118C, rtT118G, rtQ267L, rtI269L, rtA317S, rtK333Q, and rtN337H. Both the rtS106 and rtT118 sites demonstrated a variable nucleotide substitution of 50% C and 50% G on a chromatogram (Figure 2). Although we observed the patient for a few additional weeks, the AST and ALT levels increased to 202 IU/L and 539 IU/L, respectively. We changed the therapy from tenofovir to entecavir with a regimen of 0.5 mg once daily. After 4 mo, the HBV DNA titer decreased to 267 copies/mL. The AST and ALT levels normalized to 32 IU/L and 26 IU/L, respectively (Figure 3). HBeAg seroconversion had not yet occurred.

**DISCUSSION**

The treatment of chronic hepatitis B has improved in the last decade primarily because of the availability of oral nucleos(t)ide analogue antiviral agents, such as LAM, telbivudine (LdT), ADV, ETC, and TDF. These agents are well tolerated and very effective in suppressing viral replication, and they appear to be safe, to the best of our knowledge and experience. The major limitation of long-term antiviral therapy for chronic hepatitis B is the emergence of drug resistance followed initially by an increase in HBV DNA level (virologic breakthrough) and then by an increase in serum aminotransferase level (biochemical breakthrough)[[1](#_ENREF_15)4].

Antiviral resistance is likely to develop primarily because the mutation rate during HBV replication is high and viral replication is increased in response to selection pressure[4,5]. Mutation and resistance are determined by three factors: viral fitness, nucleos(t)ide analogue potency, and the genetic barrier to resistance[15]. Viral fitness refers to the ability for viral replication in a defined environment. The potency of a nucleos(t)ide analogue describes its ability to inhibit HBV replication by acting as a substrate. The genetic barrier to resistance refers to the number of substitutions in the HBV polymerase reverse transcriptase (RT) domain required for the development of resistance[14]. Of the above three factors, nucleos(t)ide analogue potency and the genetic barrier to resistance are properties of antiviral agents. A higher nucleos(t)ide analogue potency and genetic barrier corresponds to a lower mutation rate[16].

The results of longitudinal study of TDF therapy demonstrated no resistance development throughout 8 years of treatment[[1](#_ENREF_14)7]. This result is possible because TDF provides the combination of a high genetic barrier, potent viral suppression, and reduced fitness of resistant viruses. Thus, TDF has been one of the drugs recommended as a first-line therapy for CHB patients[18,19]. TDF is also recommended for patients who have developed resistance to LAM, ETC, or LdT[20]. Several case reports and retrospective cohort stud­ies also demonstrated the clinical efficacy of TDF in ETC-resistant or ETC-refractory patients[12,21]. In one study, the HBV DNA in some patients who experienced a virologic breakthrough while on TDF therapy contained an RT mutation site such as rtL101L/F, rtA307A/T, rtV173L+rtL180M+rtM204V, or rtA181T. However, these substitutions did not result in reduced susceptibility to TDF, and most of the patients did not adhere to treatment[[1](#_ENREF_12)1]. The rtA194T HBV polymerase mutation that was recently identified in HIV/HBV-coinfected patients treated with TDF did not confer resistance to TDF as the sole mutation in vitro[22]. In another study, phenotypic analyses revealed that the presence of the rtA194T mutation combined with the rtL180M and rtM204V mutations resulted in a greater than 10-fold increase in the IC50 for TDF compared to the wild type[23]. However, those sites have not been confirmed as mutation sites affecting TDF resistance because TDF resistance was not reported. Further studies are needed to assess the extent to which these mutations are associated with TDF resistance in HBV infection.

Reports on TDF resistance are difficult to find because TDF resistance is rare. A few years ago, a case of TDF resistance was reported in a chronic hepatitis B (CHB) patient who received sequential nucleos(t)ide therapy[24]. TDF resistance with virologic and biochemical breakthroughs had occurred during TDF rescue therapy after consecutive LAM, ETC, and LAM+ADV treatment failures. The identified HBV DNA mutation sites were rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rtS223A, rtT184A/L, rtR153Q, and rtV191I, which were previously known as mutation sites related to LAM, ETC and ADV resistance. Recently, Lee *et al*[13] reported two TDF-resistant patients during "The Liver Week 2017" symposium in the United States. The patients described in this report had also previously taken other antiviral drugs and demonstrated multidrug resistance. However, the authors detected seven mutations in the HBV DNA, including three new substitutions, namely, rtS106C, rtH126Y, and rtD134E, which were collectively termed CYE. The TDF IC50 values for wild-type HBV and the CYE mutant were 3.8 ± 0.6 μmol/L and 14.1 ± 1.8 μmol/L, respectively. However, the CYE mutation site was not definitively identified as the site related to TDF resistance, although the TDF IC50 was higher in the CYE mutant than in the wild type. The TDF resistance described in the previous two reports developed after the failure of treatment with other nucleos(t)ide analogues. The patient in the present study had no history of nucleos(t)ide analogue treatment and showed complete viral suppression before the development of TDF resistance. It is not clear whether all 9 HBV RT mutation sites identified in the current patient were associated with TDF resistance. However, the accumulation of this mutational data is helpful for confirming the sites associated with TDF resistance. Further in vitro study is needed to reveal whether the 9 mutation sites are associated with an increased TDF IC50 .

**ARTICLE HIGHLIGHTS**

***Case characteristics***

The patient had not complained of any specific symptoms.

***Clinical diagnosis***

The hepatitis B virus DNA titer rebounded to 7.5 log10 copies/mL at 43 mo after TDF treatment in a treatment-naive patient.

***Differential diagnosis***

We performed full genome sequencing to find other mutation sites to know it is associated with tenofovir disoproxil fumarate (TDF) resistance.

***Laboratory diagnosis***

We performed full genome sequencing to find TDF mutation sites and the results showed mutations at 9 sites, namely, rtY9H, rtL91I, rtS106C, rtS106G, rtT118C, rtT118G, rtQ267L, rtI269L, rtA317S, rtK333Q, and rtN337H.

***Imaging diagnosis***

We had not performed any specific imaging methods.

***Pathological diagnosis***

We had not performed any specific pathological methods.

***Treatment***

We changed the therapy from tenofovir to entecavir with a regimen of 0.5 mg once daily.

***Experiences and lessons***

We have to consider possibility of TDF resistance although its rarity.

**REFERENCES**

1 **Lok AS**. Chronic hepatitis B. *N Engl J Med* 2002; **346**: 1682-1683 [PMID: 12037146 DOI: 10.1056/NEJM200205303462202]

2 **Perz JF**, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006; **45**: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]

3 **Schweitzer A**, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* 2015; **386**: 1546-1555 [PMID: 26231459 DOI: 10.1016/S0140-6736(15)61412-X]

4 **Pawlotsky JM,** Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. *Gastroenterology* 2008; **134**: 405-415 [PMID: 18242209 DOI: 10.1053/j.gastro.2007.11.036]

5 **Lok AS**, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007; **45**: 507-539 [PMID: 17256718 DOI: 10.1002/hep.21513]

6 **Hosaka T**, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. *Hepatology* 2013; **58**: 98-107 [PMID: 23213040 DOI: 10.1002/hep.26180]

7 **Liaw YF**, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 2004; **351**: 1521-1531 [PMID: 15470215 DOI: 10.1056/NEJMoa033364]

8 **Lok AS**, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. *Gastroenterology* 2003; **125**: 1714-1722 [PMID: 14724824]

9 **Chang TT**, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2006; **354**: 1001-1010 [PMID: 16525137 DOI: 10.1056/NEJMoa051285]

10 **Tenney DJ**, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. *Hepatology* 2009; **49**: 1503-1514 [PMID: 19280622 DOI: 10.1002/hep.22841]

11 **Kitrinos KM**, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. *Hepatology* 2014; **59**: 434-442 [PMID: 23939953 DOI: 10.1002/hep.26686]

12 **Yip B**, Chaung K, Wong CR, Trinh HN, Nguyen HA, Ahmed A, Cheung R, Nguyen MH. Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. *Dig Dis Sci* 2012; **57**: 3011-3016 [PMID: 23010744 DOI: 10.1007/s10620-012-2402-2]

13 **Lee JH,** Lee YB, Cho HK, Cho YY, Cho EJ, Kim YJ, Yoon JH, Zoulim F, Kim KH; The Seoul Liver Group. Identification of a Triple Mutation that Confers Tenofovir Resistance in Chronic Hepatitis B Patients. *Hepatology* 2017; **66** Suppl 1: S69-S70

14 **Hulgan T**, Haas DW. Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity. *J Infect Dis* 2006; **194**: 1471-1474 [PMID: 17083029 DOI: 10.1086/508550]

15 **Richman DD**. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. *Hepatology* 2000; **32**: 866-867 [PMID: 11003636 DOI: 10.1053/jhep.2000.18194]

16 **Ghany MG**, Doo EC. Antiviral resistance and hepatitis B therapy. *Hepatology* 2009; **49**: S174-S184 [PMID: 19399794 DOI: 10.1002/hep.22900]

17 **Liu Y**, Corsa AC, Buti M, Cathcart AL, Flaherty JF, Miller MD, Kitrinos KM, Marcellin P, Gane EJ. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. *J Viral Hepat* 2017; **24**: 68-74 [PMID: 27658343 DOI: 10.1111/jvh.12613]

18 **European Association For The Study Of The Liver.** EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 2012; **57**: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]

19 **Lok AS**, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology* 2009; **50**: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]

20 **Villet S**, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, Zoulim F. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. *J Hepatol* 2007; **46**: 531-538 [PMID: 17239478 DOI: 10.1016/j.jhep.2006.11.016]

21 **Kim YJ**, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. *World J Gastroenterol* 2012; **18**: 6996-7002 [PMID: 23322999 DOI: 10.3748/wjg.v18.i47.6996]

22 **Delaney WE 4th**, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. *Antimicrob Agents Chemother* 2006; **50**: 2471-2477 [PMID: 16801428 DOI: 10.1128/AAC.00138-06]

23 **Sheldon J**, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. *Antivir Ther* 2005; **10**: 727-734 [PMID: 16218172]

24 **Lee HW**, Chang HY, Yang SY, Kim HJ. Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy. *J Clin Virol* 2014; **60**: 313-316 [PMID: 24836314 DOI: 10.1016/j.jcv.2014.03.018]

**P-Reviewer:** Cheung R, Gunal O, Osna NA **S-Editor:** Wang XJ

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** South Korea

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

****

**Figure 1 Full sequencing analysis of the hepatitis B virus reverse transcriptase gene from the patient (Korean sample).** The sequence analysis shows that mutations occurred at 9 sites compared to the wild-type genotype C (the patient was infected with genotype C). The rt106 and rt118 sites are expressed as “?” because the sites contained a substitution by 2 different nucleotides.

**Figure 2 Chromatogram of the hepatitis B virus reverse transcriptase gene from the patient.** The rt101 (arrow head) and rt118 (arrow) sites are shown as a double line because the site contained a substitution by 2 different nucleotides (cytosine and guanine).



**Figure 3 Clinical course of the patient.** Hepatitis B virus DNA became undetectable after 16 mo of antiviral treatment with TDF. Virologic and biochemical breakthroughs occurred at 43 mo after treatment initiation.